Search results
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 5 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 2 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Motley Fool via Yahoo Finance· 5 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 17 hours agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 19 hours agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 21 hours agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via AOL· 13 hours ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
The Motley Fool via AOL· 4 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 21 hours agoThe trial results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via AOL· 5 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...